Skip to main content
. 2025 Feb 19;15:6022. doi: 10.1038/s41598-025-90135-8

Table 3.

Characteristics of AE reports associated with HBV from VEARS between 1990–2023.

Characteristics N Proportion (%)
Total 54,136 100%
Gender Male 19,862 36.69%
Female 30,657 56.63%
Unknown 3617 6..68%
Age(year)  ≤ 1 15,638 28.79%
 > 1, < 2 2650 4.88%
 ≥ 2, < 12 6287 11.61%
 ≥ 12, < 22 7418 13.70%
 ≥ 22, < 42 12,933 23.81%
 ≥ 42, < 62 7815 14.39%
 ≥ 62, < 120 1049 1.93%
Administration dose 1 15,997 29.55%
2 13,776 25.45%
3 11,183 20.66%
4 1667 3.08%
5 332 0.61%
6 133 0.25%
7 +  41 0.08%
Unknown 10,966 20.26%
NA 41 0.08%
Outcome Died 872 1.61%
Life threatening 1093 2.02%
Emergency room 17,206 31.78%
Hospitalized 3801 7.02%
Prolonged hospitalization 323 0.60%
Disability 1326 2.45%
Congenital anomaly or birth defect 1022 1.89%
healthcare professional office/clinic visit 1302 2.41%
Emergency room/department or urgent care 1250 2.31%
Unknown 31,330 57.87%
Onset time(day) 0 26,022 /
 > 0, < 30 18,853 /
 ≥ 30, < 60 985 /
 ≥ 60, < 90 443 /
 ≥ 90, < 120 307 /
 ≥ 120 1631 /
average 34.9 /

AE adverse event, HBV hepatitis B vaccine, VAERS vaccine adverse event reporting system.